Every material Form 8-K PALATIN TECHNOLOGIES INC has filed with the SEC since November 06, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Palatin Technologies notified the NYSE American on May 18, 2026 that it plans to voluntarily withdraw its common stock listing and transfer it to the Nasdaq Capital Market, which has approved the listing. The stock will keep the symbol PTN, and the company says no action is required from existing stockholders.
NYSE American listing expected to cease at the close of trading on May 28, 2026.
Trading on the Nasdaq Capital Market expected to begin May 29, 2026, under the symbol PTN.
CEO Carl Spana said the company believes the move will improve stock visibility, trading liquidity and access to institutional investors.
The filing contains no financial results; the disclosure concerns the listing transfer only.
Palatin Technologies closed its upsized public offering on November 12, 2025, after underwriters fully exercised their over-allotment option, bringing gross proceeds to approximately $18.2 million. The closing regained compliance with the NYSE American stockholders' equity listing standard, and the stock resumed trading under the symbol PTN that day; the company plans to use the net proceeds for its obesity program and working capital.
Gross proceeds were approximately $18.2 million, including about $2.37 million from the over-allotment option, at $6.50 per share or pre-funded warrant.
The offering included Series J warrants and Series K warrants at an exercise price of $8.125 for the Series K warrants, and up to $18.2 million more could come from cash exercise of the milestone-related Series J warrants, which is not guar
The company regained compliance with NYSE American's Stockholders' Equity Rule, and PTN resumed trading on November 12, 2025.
Net proceeds are intended for the obesity program and general corporate purposes.
Palatin Technologies agreed on November 5, 2025 to sell 2,430,769 shares (or pre-funded warrants) at $6.50 per share, together with Series J and Series K warrants, with gross proceeds expected to be about $15.8 million. The company said the closing should restore compliance with the NYSE American stockholders' equity rule, and its common stock is expected to resume trading under PTN on November 12, 2025, but the new shares and warrants add potential dilution for existing holders.
Offering of 2,430,769 shares or pre-funded warrants at $6.50 per share, with Series J and Series K warrants, for expected gross proceeds of about $15.8 million
Series J warrants have a $6.50 exercise price; Series K warrants have an $8.125 exercise price and are tied to an FDA acceptance of an obesity compound IND
Closing is expected on or about November 12, 2025, the same day trading is expected to resume on NYSE American under PTN
Expected net proceeds of $14.7 million; up to an additional $15.8 million could come from Series J warrant exercises, which is not guaranteed
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PALATIN TECHNOLOGIES INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →